nderstanding the magnitude and kinetics of the serological responses to killed Oral Cholera Vaccine (OCV) when given 2 to 3 years after an initial receipt of OCV in Cameroon

Meilleur Acces aux Soins de Sante0 个研究点目标入组 360 人开始时间: 2021年1月21日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•1.Age =1 year at the time of the 2017 OCV campaign, stratified into different age groups
•2.Living in the Mogode Health Area where the OCV campaign was carried out
•3.Good health condition, without clinically significant medical history (by participant or guardian, in case of minor)
•4.Not pregnant for female subjects (confirmed by a urine pregnancy test)
•5.Available to participate for the study duration, including all planned follow-up visits for up to 42 days from the time of screening.
•6.Signed informed consent

•1.Presence of a significant medical or psychiatric condition (Examples include: Diagnosis and treatment of TB or HIV; renal insufficiency; hepatic disease; oral or parenteral medication known to affect the immune function , such as corticosteroids, other immunosuppressant drugs; or behavioural or memory issues)
•2.Receipt of an investigational product (within 30 days before vaccination).
•3.History of diarrhoea in 7 days prior to first dose of vaccine (defined as =3 unformed loose stools in 24 hours).
•4.History of chronic diarrhea (lasting for more than 2 weeks in the past 6 months)
•5.Current use of laxatives, antacids, or other agents to lower stomach acidity?
•6.Planning to become pregnant in the next 2 months

发起方

Meilleur Acces aux Soins de Sante